Compare Domino's Pizza, Inc. (DPZ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Twist Bioscience Corp — how do they compare? Domino's Pizza, Inc. trades at $308 (market cap $10.21B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Domino's Pizza, Inc. and Twist Bioscience Corp are close in size by market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Twist Bioscience Corp for 27 Days on average.
| DPZ | TWST | |
|---|---|---|
Market Cap | $10.21B | $10.08B |
Volume | 916,737 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $205.00 |
52-Week Low | $282.89 | $25.45 |
Typical Hold Time | 106 Days | 27 Days |
Enterprise Value | $15.17B | $10.01B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $303.10, showing minimal daily movement with a 0.08% gain. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while recent earnings misses and high debt levels of $5.7 billion create fundamental concerns. However, analyst sentiment remains positive with a $373 consensus price target representing 23% upside potential, supported by consistent revenue growth and strong profitability margins.
The outlook balances strong cash flow generation and market leadership against significant leverage and recent earnings disappointments. Investment opportunity exists in the valuation discount to analyst targets, but risks include debt servicing costs, competitive pressures, and execution challenges in maintaining growth momentum amid economic uncertainty.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
